Cambrex Corp., an East Rutherford-based manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients, announced Thursday that it is spending approximately $5 million to expand its laboratory in Karlskoga, Sweden.
The expansion will expand capability and capacity for process development and scale up, handling potent substances, crystallization studies and solid phase characterization, it said. It will also have space for a new technical laboratory, two analytical development and quality control laboratories, and additional office space for 12 scientists and chemists.
Construction is slated for the end of the second quarter of 2018 with completion set for the second quarter of 2019.
The expanded space will include a new technical laboratory, allow for handling of potent substances at a large scale, high pressure
“We have a rich history in chemistry at our Karlskoga site, dating back 120 years to Alfred Nobel himself in 1896,” said Bjarne Sandberg, managing director, Cambrex Karlskoga. “The new laboratory expansion will enhance our ability to provide global customers with scientific and chemical excellence.”